Magnendo, an MIT spinout building a magnetic robotic navigation platform for neuro-endovascular procedures, has closed an $18 million Series A financing led by Penumbra with participation from a syndicate of new and existing institutional investors. The Newton, Massachusetts company will use the round to productise its preclinically validated system and prepare for first-in-human clinical studies.
Magnets for the stroke race against the clock
Mechanical thrombectomy has become the standard of care for acute ischemic stroke, but reaching the clot inside tortuous cerebral vessels remains one of the most technically demanding parts of the procedure. Magnendo's platform pairs magnetically steerable guidewires with robotic control, advanced imaging and intelligent navigation software to help operators reach the lesion faster and more consistently across anatomies.
"Our mission is to redefine endovascular access through magnetic robotic navigation, enabling physicians to reach the treatment site faster, more reliably, and with greater consistency," said Yoonho Kim, founder and CEO of Magnendo. Preclinical evaluations, the company said, showed substantial reductions in navigation times and improved procedural consistency across operators.
Penumbra plants a flag in endovascular robotics
Penumbra is a natural strategic partner: the neurovascular specialist is itself being acquired by Boston Scientific in a roughly $14.5 billion deal announced earlier in 2026, and has been building a reality-capture stack around its aspiration thrombectomy franchise. "Magnendo has developed an elegant and pragmatic approach to one of the most challenging aspects of endovascular intervention," said Sruthi Narayan, president of Penumbra.
A busy summer for surgical robotics
Magnendo's round lands as the wider surgical-robotics field pushes into new frontiers. MMI just won an FDA nod to expand its REMIND study for robotic microsurgery, while endovascular rivals such as Microbot Medical, XCath and Sentante are also pushing new platforms toward the clinic. Magnendo now joins that pipeline with fresh capital and a heavyweight strategic on the cap table.
Reporting based on coverage from MassDevice and Magnendo.